#United States #Anixa Biosciences #San Francisco #CAR-T therapy #Cleveland Clinic

Anixa Biosciences Set to Present at Nasdaq & LD Micro Inaugural SF Summit

Anixa Biosciences, Inc. is gearing up for a noteworthy presentation at the forthcoming Nasdaq & LD Micro Inaugural SF Summit, taking place on September 9, 2026. Dr. Amit Kumar, the Chairman and CEO of Anixa, will take the stage at 3:40 PM PT in Nasdaq's San Francisco headquarters, where he will unveil critical updates regarding the company’s ongoing clinical initiatives aimed at combating cancer.

The focal point of Dr. Kumar's presentation will be the progress made on Anixa’s CAR-T therapy for recurrent and treatment-resistant ovarian cancer. Currently in a Phase 1 clinical trial in partnership with the prestigious Moffitt Cancer Center, early results have been promising, showing encouraging survival rates with no observable dose-limiting toxicities to date. Such findings highlight the potential of this innovative therapy in the fight against one of the most challenging cancers.

Additionally, the presentation will address the recently concluded Phase 1 trial evaluating a therapeutic and prophylactic breast cancer vaccine developed in collaboration with the Cleveland Clinic. Notably funded by the U.S. Department of Defense, this trial successfully met all its primary endpoints, emphasizing Anixa's commitment to pioneering cancer prevention efforts.

In Dr. Kumar’s words, "We are thrilled to present at this inaugural event. The primary focus will be our breast cancer vaccine, especially in the wake of recent positive results from a Phase 3 trial for a personalized melanoma vaccine. We believe that our Phase 1 trial results for the breast cancer vaccine align favorably with those of the melanoma vaccine, notwithstanding the different methodologies employed."

Event Insights

The Nasdaq & LD Micro Inaugural SF Summit promises to convene a select gathering of public companies, where each will present their findings to an audience of institutional investors. Following each presentation, breakout sessions will allow investors to engage directly with company leadership, providing an excellent opportunity for meaningful dialogue and Q&A.

For investors interested in connecting with Anixa, they are encouraged to reach out through their LD Micro representative.

About Anixa Biosciences

Anixa Biosciences positions itself as a clinical-stage biotechnology company dedicated to advancing solutions for cancer treatment and prevention. Its noteworthy therapeutic pipeline includes liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy developed in collaboration with Moffitt Cancer Center. This innovative approach utilizes a unique CAR-T therapy that harnesses the body's immune response against cancer.

Furthermore, the company is pursuing a portfolio of vaccines targeting various cancers. This includes dual initiatives aimed at preventing and treating breast and ovarian cancer, alongside developments addressing a spectrum of significant malignancies such as those affecting the lung, colon, and prostate. Notably, the vaccine research is anchored in collaborations with the Cleveland Clinic, showcasing the efficacy of immunizing against certain proteins associated with cancer development.

Anixa follows a distinctive business model, engaging with renowned research institutions at all stages of development, thus ensuring consistent evaluation and incorporation of cutting-edge technologies in its therapeutic undertakings. For more detailed information about their initiatives, visit Anixa’s official website or connect through their various social media platforms.

Conclusion

As the date draws closer, anticipation builds for Anixa's presentation at the Nasdaq & LD Micro Summit. With innovative therapies and research efforts focused on long-overdue advancements in cancer treatment and prevention, the company is poised to make a substantial mark on the field of biotechnology and oncology.